Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223
Awaiting development [GID-HST10019] Expected publication date: TBC
Search results
221 results
-
-
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Awaiting development [GID-HST10049] Expected publication date: TBC
-
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]
Awaiting development [GID-HST10022] Expected publication date: TBC
-
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]
Awaiting development [GID-HST10039] Expected publication date: TBC
-
VTS-270 for treating Niemann-Pick type C1 (ID1267)
Awaiting development [GID-HST10020] Expected publication date: TBC
-
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]
Awaiting development [GID-HST10032] Expected publication date: TBC
-
Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) [ID3927]
Awaiting development [GID-HST10046] Expected publication date: TBC
-
Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder: interventional procedure consultation
We are listening to your views on this Interventional procedures guidance. Comments close 24 May 2022.
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 26 May 2022.
-
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 6 June 2022.
-
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 13 June 2022.
-
Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis
Awaiting development [GID-IPG10235] Expected publication date: TBC
-
Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by high spinal cord injuries
Awaiting development [GID-IPG10248] Expected publication date: TBC
-
Minimally invasive deformity correction system for the treatment of adolescent idiopathic scoliosis
Awaiting development [GID-IPG10247] Expected publication date: TBC
-
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
Awaiting development [GID-IPG10205] Expected publication date: TBC
-
Balloon disimpaction of fetal head at emergency caesarean delivery
Awaiting development [GID-IPG10220] Expected publication date: 16 November 2022
-
Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia
Awaiting development [GID-IPG10249] Expected publication date: TBC
-
Carotid artery stent placement for asymptomatic extracranial carotid stenosis
Awaiting development [GID-IPG10250] Expected publication date: TBC
-
Cryotherapy for Chronic Rhinitis
Awaiting development [GID-IPG10251] Expected publication date: TBC
-
Insertion of neo-chordae into the beating heart for mitral regurgitation
Awaiting development [GID-IPG10216] Expected publication date: 21 April 2023
-
Radiofrequency denervation for osteoarthritic knee pain
Awaiting development [GID-IPG10236] Expected publication date: 29 June 2023
-
Daridorexant for treating insomnia disorder [ID3774]
Awaiting development [GID-TA10888] Expected publication date: 16 August 2023
-
Vutrisiran for hereditary transthyretin amyloidosis [ID5074]
Awaiting development [GID-TA10954] Expected publication date: TBC
-
Deucravacitinib for treating moderate to severe plaque psoriasis [ID3859]
Awaiting development [GID-TA10855] Expected publication date: TBC
-
Dexamethasone intravitreal implant for treating diabetic macular oedema in people without a pseudophakic lens [ID3951]
Awaiting development [GID-TA10889] Expected publication date: 14 September 2022
-
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]
Awaiting development [GID-TA10909] Expected publication date: TBC
-
Test347
Awaiting development [GID-TA10949] Expected publication date: TBC
-
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Awaiting development [GID-TA10723] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Awaiting development [GID-TA10728] Expected publication date: TBC
-
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Awaiting development [GID-TA10747] Expected publication date: TBC
-
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Awaiting development [GID-TA10748] Expected publication date: TBC
-
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Awaiting development [GID-TA10750] Expected publication date: TBC
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Awaiting development [GID-TA10741] Expected publication date: TBC
-
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]
Awaiting development [GID-TA10821] Expected publication date: TBC
-
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]
Awaiting development [GID-TA10720] Expected publication date: TBC
-
Liposomal bupivacaine for treating postoperative pain [ID3799]
Awaiting development [GID-TA10681] Expected publication date: TBC
-
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)
Awaiting development [GID-TA10306] Expected publication date: TBC
-
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)
Awaiting development [GID-TA10426] Expected publication date: TBC
-
Rivaroxaban for treating chronic heart failure [ID1462]
Awaiting development [GID-TA10393] Expected publication date: TBC
-
Dulaglutide for treating type 2 diabetes [ID1451]
Awaiting development [GID-TA10439] Expected publication date: TBC
-
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]
Awaiting development [GID-TA10861] Expected publication date: TBC
-
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]
Awaiting development [GID-TA10795] Expected publication date: TBC
-
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Awaiting development [GID-TA10716] Expected publication date: TBC
-
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Awaiting development [GID-TA10843] Expected publication date: TBC
-
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]
Awaiting development [GID-TA10848] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]
Awaiting development [GID-TA10683] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
Awaiting development [GID-TA10895] Expected publication date: TBC
-
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]
Awaiting development [GID-TA10896] Expected publication date: TBC
-
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]
Awaiting development [GID-TA10897] Expected publication date: TBC